A heart transplant candidate tells his EECP patient story from his experience at Global Cardio Care Centers.
Ronald S. Weaver, MD, owner of Global Cardio Care Centers in Inglewood, Calif., today announced a heart transplant patient with cardiomyopathy has successfully completed a course of Enhanced External Counterpulsation (EECP) therapy at Global Cardio Care Centers and is no longer a candidate for heart transplant.
The patient, a 55-year-old Hispanic male, also completed 35 days of the Sara Soulati Health For Life Program, a nutrition and exercise lifestyle program in combination with EECP treatment that helps prevent and reverse cardiovascular disease.
The patient, under the care of his cardiologist at Scripps Health in San Diego, was taking about 15 medications daily and had 13 heart procedures to fight ongoing angina pectoris and congestive heart failure with a history of heart attack. His cardiologist gave him a low chance for survival and put him on the heart transplant list.
After 35 hours of EECP treatment (recommended course), the patient shared in a YouTube video (see below) that he felt improvement in his chest pain (angina pectoris), blood pressure, ejection fraction (fraction of blood pumped out with each heart beat), increased mobility and a reduction in daily medications from 15 to 3.
Upon the patient’s return to his cardiologist at Scripps Health, he was removed from the heart transplant list because his stronger heart muscle resulted in an increased ejection fraction due to EECP. To date, the patient remains off the heart transplant list.
Ronald S. Weaver, MD Comment
“This is a classic example of how EECP therapy can benefit patients with end-stage cardiovascular disease. It’s a solid example of how EECP is positively affecting the U.S. healthcare cost burden because one heart transplant costs more than $1.2 million, as compared to one course of EECP treatment, which costs less than $6,000 for 35 hours of EECP,” said Ronald S. Weaver, MD, owner of Global Cardio Care Centers. “The fact that this patient with end stage ischemia cardiomyopathy was able to come off a heart transplant list because of EECP, along with a serious lifestyle change, suggests there are more people who could also benefit from this therapy.”
Patients come to Global Cardio Care Centers with advanced angina pectoris, congestive heart failure, and failed bypass surgery with or without many co-morbid conditions that prevent more costly and risky invasive procedures.
Two additional current patients who received EECP at Global Cardio Care Centers did not need to go forward with scheduled heart transplant surgeries, which would have added to the already extensive burden on the U.S. healthcare system.